Clinical Trial Update: The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome

View source ↗

Summary

Clinical trial update examining the roles of TCF7L2 and SLC30A8 in antipsychotic-induced metabolic syndrome in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Schizophrenia

Snippet

Sponsor: Central South University | Conditions: Schizophrenia, Metabolic Syndrome | Status: UNKNOWN